112 related articles for article (PubMed ID: 2403803)
1. Anti-idiotypic therapy of leukemias and lymphomas.
Stevenson FK; George AJ; Glennie MJ
Chem Immunol; 1990; 48():126-66. PubMed ID: 2403803
[TBL] [Abstract][Full Text] [Related]
2. Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1.
George AJ; Tutt AL; Stevenson FK
J Immunol; 1987 Jan; 138(2):628-34. PubMed ID: 3491853
[TBL] [Abstract][Full Text] [Related]
3. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
4. Idiotypic variation in a human B lymphoma cell line.
Berinstein N; Campbell MJ; Lam K; Carswell C; Levy S; Levy R
J Immunol; 1990 Jan; 144(2):752-8. PubMed ID: 2295809
[TBL] [Abstract][Full Text] [Related]
5. Surface immunoglobulin of B-lymphocytic tumours as a therapeutic target.
Stevenson GT; Glennie MJ
Cancer Surv; 1985; 4(1):213-44. PubMed ID: 3916080
[TBL] [Abstract][Full Text] [Related]
6. Immunization with idiotypic immunoglobulin protects against development of B lymphocytic leukemia, but emerging tumor cells can evade antibody attack by modulation.
Stevenson FK; Gordon J
J Immunol; 1983 Feb; 130(2):970-3. PubMed ID: 6600259
[TBL] [Abstract][Full Text] [Related]
7. Molecules recognized by anti-idiotypic monoclonal antibodies to the B cell lymphoma, BCL1.
Tamura GS; McGrath MS; Weissman IL
J Mol Cell Immunol; 1987; 3(4):243-53. PubMed ID: 3509925
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody].
Kon S
Gan To Kagaku Ryoho; 1988 May; 15(5):1685-92. PubMed ID: 3259417
[TBL] [Abstract][Full Text] [Related]
9. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
[TBL] [Abstract][Full Text] [Related]
10. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D
Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy of a murine B cell tumor with antibodies and F(ab')2 fragments against idiotypic determinants of its cell surface IgM.
Perek Y; Hurwitz E; Burowski D; Haimovich J
J Immunol; 1983 Sep; 131(3):1600-3. PubMed ID: 6604103
[TBL] [Abstract][Full Text] [Related]
12. Idiotype variants emerging after anti-idiotype monoclonal antibody therapy of a murine B cell lymphoma.
Weiner GJ; Kaminski MS
J Immunol; 1989 Jan; 142(1):343-51. PubMed ID: 2783325
[TBL] [Abstract][Full Text] [Related]
13. Surface immunoglobulins are involved in the interaction of protein A with human B cells and in the triggering of B cell proliferation induced by protein A-containing Staphylococcus aureus.
Romagnani S; Giudizi MG; Biagiotti R; Almerigogna F; Maggi E; Del Prete G; Ricci M
J Immunol; 1981 Oct; 127(4):1307-13. PubMed ID: 6974188
[TBL] [Abstract][Full Text] [Related]
14. Demonstration of immunoglobulin-related molecules on human peripheral blood T lymphocytes using chicken anti-F(ab')2 and anti-IgM antibodies.
Haegert DG
Immunology; 1980 Nov; 41(3):663-71. PubMed ID: 6161876
[TBL] [Abstract][Full Text] [Related]
15. Strategies for production of monoclonal anti-idiotype antibodies against human B cell lymphomas.
Thielemans K; Maloney DG; Meeker T; Fujimoto J; Doss C; Warnke RA; Bindl J; Gralow J; Miller RA; Levy R
J Immunol; 1984 Jul; 133(1):495-501. PubMed ID: 6609992
[TBL] [Abstract][Full Text] [Related]
16. Circulating monoclonal IgM proteins in B cell chronic lymphocytic leukemia: their identification, characterization and relationship to membrane IgM.
Qian GX; Fu SM; Solanki DL; Rai KR
J Immunol; 1984 Dec; 133(6):3396-400. PubMed ID: 6333459
[TBL] [Abstract][Full Text] [Related]
17. Idiotypic determinants on human T cells and modulation of human T cell responses by anti-idiotypic antibodies.
Geha RS
J Immunol; 1984 Oct; 133(4):1846-51. PubMed ID: 6206140
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibody studies in B(non-T)-cell malignancies.
Shimoyama M; Minato K; Tobinai K; Nagai M; Hirose M
Jpn J Clin Oncol; 1983 Sep; 13(3):477-88. PubMed ID: 6417373
[TBL] [Abstract][Full Text] [Related]
19. Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B-lymphoproliferative disorders specifically react with patients' tumor cells.
Rinaldi M; Ria F; Parrella P; Signori E; Serra A; Ciafrè SA; Vespignani I; Lazzari M; Farace MG; Saglio G; Fazio VM
Cancer Res; 2001 Feb; 61(4):1555-62. PubMed ID: 11245465
[TBL] [Abstract][Full Text] [Related]
20. Loss of surface-bound antibody accompanying the anti-complementary modulation of leukemic B cell immunoglobulin: contrasting effects of antibodies directed against idiotypic and constant regions.
Gordon J; Anderson VA; Stevenson GT
J Immunol; 1982 Jun; 128(6):2863-9. PubMed ID: 6804570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
